Organization (Industry)
EVER Neuro Pharma GmbH
ClinicalTrials.gov lists EVER Neuro Pharma GmbH as lead sponsor of 10 trials. It has 9 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers EVER Neuro Pharma GmbH: 10 lead-sponsored trials and 2 legal-entity registrations. The parent company on record for EVER Neuro Pharma GmbH is EVER Pharma Holding Ges.m.b.H., which does not have its own page on this site.
Disease areas (15)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Stroke | 10 |
| Ischemic Stroke | 6 |
| Dementia | 4 |
| Alzheimer Disease | 2 |
| Dementia, Vascular | 2 |
Showing 5 of 15 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 1 |
| 2018 | 1 |
| 2016 | 1 |
| 2014 | 1 |
| 2013 | 1 |
| 2011 | 1 |
| 2006 | 2 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (9)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Cerebrolysin | Cerebral Infarction | Phase 2 | 1 |
| Cerebrolysin | CADASIL | Phase 2 | 1 |
| Cerebrolysin | Cerebral Small Vessel Diseases | Phase 2 | 1 |
| NACL 0.9% | Cerebral Infarction | Phase 2 | 1 |
| NACL 0.9% | Dementia | Phase 2 | 1 |
Showing 5 of 9 active programs.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Cerebrolysin | 9 |
| DONEPEZIL | 1 |
| NACL 0.9% | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 3 hit target (n=3) | 0 of 3 on time (n=3) |
Journals published in (14)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| European journal of neurology | 3 |
| International journal of stroke : official journal of the International Stroke Society | 3 |
| Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | 3 |
| Stroke | 2 |
| The New England journal of medicine | 2 |
Showing 5 of 14 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 0 | 2011-10-11 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Ever Neuro Pharma GmbH | Unterach Am Attersee, AT | EMA | |
| Ever Neuro Pharma GmbH | Ebensee, AT | EMA |
Organization relationships (3)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| acromion GmbH | Co sponsors trial with | 1 |
| idv Datenanalyse & Versuchsplanung | Co sponsors trial with | 1 |
| XClinical GmbH | Co sponsors trial with | 1 |
Latest dated events (15)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2024-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-11-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2022-11-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2021-06-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 15 events.
Biomarker capability evidence (12)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BCHE | Trial sponsor | Named in trial inclusion criteria |
| F3 | Trial sponsor | Named in trial inclusion criteria |
| BCHE | Trial sponsor | Named in trial exclusion criteria |
| EPO | Trial sponsor | Named in trial exclusion criteria |
| EPO | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 12 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.